Congenital Hyperinsulinism Market: By Treatment, Dietary Management, Surgery, and Others), By Disease Type, By Diagnosis Method, By Route of Administration, By End Users and Region Forecast 2019-2030
Congenital Hyperinsulinism Market was valued at US$ 182 million in 2023 and is poised to grow at a CAGR of 5.5% over 2023-2029. Congenital hyperinsulinism (CHI or HI), refers to a variety of congenital disorders which is characterized by inappropriate and unregulated insulin secretion from the beta-cells of the pancreas, causing Hyperinsulinaemic hypoglycaemia (HH), and the most common cause of severe CHI are mutations in ABCC8 and KCNJ11 genes. Based on the treatment type, the drug therapy segment’s Octreotide is anticipated to dominate the market share over the forecast period. According to the National Organization for Rare Disorders, the incidence of congenital hyperinsulinism is approximately 1/25,000 to 1/50,000 births. Growing awareness about congenital hyperinsulinism and the increased R&D activities for the development of novel therapies will act as the congenital hyperinsulinism market growth drivers. However, the high cost of treatment would be the restraining factor for the market. Advancements in diagnostic techniques and novel approaches to minimize side effects are opportunities for key players in the market for the expansion of the market.
Study Period
2025-2031Base Year
2024CAGR
5.5%Largest Market
North-AmericaFastest Growing Market
North-America
Initiatives by government and non-government organizations to create awareness of congenital hyperinsulinism treatment and increasing investments by pharmaceutical companies will impact the growth of the market. For example, Congenital Hyperinsulism International, focused on providing support such as disease diagnosis and disease management to the patient with CHI, held a family conference, in August 2022. For instance, in March 2022, Zealand Pharma completed a phase-III clinical trial for Dasiglucagon to control blood sugar in infants with congenital hyperinsulinism. Moreover, the other emerging therapies, such as RZ358, CSI-Glucagon, Pasireotide, and others will participate in the growth of the market. Thus, the increased awareness, research, and development for rare disorders will lead to the growth of the market within the forecast period. However, without the proper line of treatment for the disease, the growth of the market could get hampered.
The congenital hyperinsulinism market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to the National Organization for Rare Disorders, about 60% of babies with CHI are diagnosed during the first month of life, and an additional 30% are diagnosed later in the first year. In communities where marriage between blood relatives occurs, the frequency can get 1 in 2,500 children for CHI. The incidence of persistent forms of CHI in the UK has been reported to be 1:28,389, and 1:13,500 in Finland. The North American congenital hyperinsulinism market is expected to dominate the market over the forecast period, majorly due to highly developed healthcare systems in the United States and Canada with the availability of healthcare policies and ongoing trials in the region. The Asia Pacific region is also growing at a faster rate owing to the increasing prevalence and incidence of diabetes population and the evolving healthcare infrastructure.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2025-2031 |
|
Market Size in 2023 |
US$ 182 million |
|
Market CAGR |
5.5% |
|
By Treatment Type |
|
|
By Disease Type |
|
|
By Diagnosis Method |
|
|
By Route of Administration |
|
|
By End User |
|
Download Free Sample Report
The Congenital Hyperinsulinism market was valued at US$ 182 million in 2022 and is expected to grow at a 5.5% CAGR over the forecast period 2023 – 2029.
Advancements in diagnostic techniques and novel approaches to minimize side effects are the key opportunities for the Congenital Hyperinsulinism market.
Growing awareness about congenital hyperinsulinism and the increased R&D activities for the development of novel therapies are the growth drivers in the Congenital Hyperinsulinism market.
Eli Lilly, IVAX Pharmaceuticals, Teva Pharmaceuticals, Novo Nordisk, Novartis AG, Rezolute, Inc., Xeris Pharmaceuticals, Eiger BioPharmaceuticals., Zealand Pharma A/S, Hanmi Pharmaceutical Co., Ltd., Crinetics Pharmaceuticals, Inc., and AmideBio LLC are a few companies operating in the Congenital Hyperinsulinism market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
